Alan Zwart

1.8k total citations
39 papers, 1.4k citations indexed

About

Alan Zwart is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Alan Zwart has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Alan Zwart's work include Prostate Cancer Diagnosis and Treatment (8 papers), Prostate Cancer Treatment and Research (8 papers) and Endoplasmic Reticulum Stress and Disease (7 papers). Alan Zwart is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (8 papers), Prostate Cancer Treatment and Research (8 papers) and Endoplasmic Reticulum Stress and Disease (7 papers). Alan Zwart collaborates with scholars based in United States, United Kingdom and Finland. Alan Zwart's co-authors include Robert Clarke, Rebecca B. Riggins, Anni Wärri, Ayesha N. Shajahan‐Haq, Anatasha Crawford, Katherine L. Cook, David R. Soto‐Pantoja, M. Idalia Cruz, Yuelin J. Zhu and Leena Hilakivi‐Clarke and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Molecular and Cellular Biology.

In The Last Decade

Alan Zwart

34 papers receiving 1.4k citations

Peers

Countries citing papers authored by Alan Zwart

Since Specialization

Citations

This map shows the geographic impact of Alan Zwart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Zwart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Zwart more than expected).

Fields of papers citing papers by Alan Zwart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Zwart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Zwart. The network helps show where Alan Zwart may publish in the future.

Co-authorship network of co-authors of Alan Zwart

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Zwart. A scholar is included among the top collaborators of Alan Zwart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Zwart. Alan Zwart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer 2025 ·Frontiers in Oncology ·(unknown), Min Jung Koh, (unknown), R Collins, (unknown), (unknown), (unknown), Alan Zwart, Mark Fallick, Deepak Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Sean P. Collins	0
2	Impact of neoadjuvant relugolix on patient-reported sexual function and bother 2024 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Alan Zwart, (unknown), Dinesh Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Rachel Rubin, Sean P. Collins	1
3	The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue 2024 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Alan Zwart, (unknown), Deepak Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Sean P. Collins	0
4	Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer 2024 ·Cureus ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Alan Zwart, (unknown), Thomas Yung, Deepak Kumar, Nima Aghdam, Paul Leger, Nancy A. Dawson, Simeng Suy, Sean P. Collins	0
5	Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer 2024 ·Frontiers in Oncology ·Michael Repka, Tamir Sholklapper, Alan Zwart, (unknown), (unknown), Thomas Yung, Siyuan Lei, Brian T. Collins, (unknown), Simeng Suy, (unknown), Amar U. Kishan, Sean P. Collins	2
6	Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer 2023 ·Frontiers in Oncology ·(unknown), Jerry Xiao, (unknown), (unknown), (unknown), Alan Zwart, (unknown), Thomas Yung, (unknown), Mark Fallick, Deepak Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Sean P. Collins	1
7	Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes 2023 ·Frontiers in Oncology ·(unknown), Tamir Sholklapper, (unknown), (unknown), Siyuan Lei, Abdul Rashid, (unknown), Alan Zwart, (unknown), (unknown), Thomas Yung, Nima Aghdam, Brian T. Collins, Simeng Suy, Deepak Kumar, (unknown), Keith Kowalczyk, Nancy A. Dawson, Sean P. Collins	1
8	Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer 2022 ·Frontiers in Oncology ·(unknown), Alan Zwart, (unknown), (unknown), Thomas Yung, Brian T. Collins, Deepak Kumar, Simeng Suy, Nima Aghdam, Sean P. Collins	1
9	Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer 2022 ·Frontiers in Oncology ·(unknown), Tamir Sholklapper, (unknown), Alan Zwart, (unknown), (unknown), Nima Aghdam, Simeng Suy, (unknown), Keith Kowalczyk, Sean P. Collins	1
10	Autophagy and unfolded protein response (UPR) regulate mammary gland involution by restraining apoptosis-driven irreversible changes 2018 ·Cell Death Discovery ·Anni Wärri, Katherine L. Cook, Rong Hu, Lü Jin, Alan Zwart, David R. Soto‐Pantoja, Jie Liu, Toren Finkel, Robert Clarke	27
11	Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer 2016 ·Cancer Research ·Katherine L. Cook, David R. Soto‐Pantoja, Pamela A.G. Clarke, M. Idalia Cruz, Alan Zwart, Anni Wärri, Leena Hilakivi‐Clarke, David D. Roberts, Robert Clarke	88
12	Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model 2016 ·JNCI Journal of the National Cancer Institute ·Leena Hilakivi‐Clarke, Anni Wärri, Kerrie B. Bouker, Xiyuan Zhang, Katherine L. Cook, Lü Jin, Alan Zwart, Nguyen Nguyen, Rong Hu, M. Idalia Cruz, Sônia de Assis, Wang Xiao, (unknown), Yue Wang, (unknown), Robert Clarke	25
13	Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer 2014 ·Clinical Cancer Research ·Katherine L. Cook, Anni Wärri, David R. Soto‐Pantoja, (unknown), M. Idalia Cruz, Alan Zwart, Robert Clarke	170
14	IFNγ Restores Breast Cancer Sensitivity to Fulvestrant by Regulating STAT1, IFN Regulatory Factor 1, NF-κB, BCL2 Family Members, and Signaling to Caspase-Dependent Apoptosis 2010 ·Molecular Cancer Therapeutics ·Yanxia Ning, Rebecca B. Riggins, (unknown), Haniee Chung, Alan Zwart, Robert Clarke	58
15	Abstract 4857: The role of autophagy in taxane resistant breast cancer models 2010 ·Cancer Research ·(unknown), Rebecca B. Riggins, Ayesha N. Shajahan‐Haq, Alan Zwart, Robert Clarke	1
16	Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells 2009 ·The Journal of Steroid Biochemistry and Molecular Biology ·Robert Clarke, Ayesha N. Shajahan‐Haq, Rebecca B. Riggins, (unknown), Anatasha Crawford, Jianhua Xuan, Yue Wang, Alan Zwart, (unknown), Minetta C. Liu	59
17	ERRγ Mediates Tamoxifen Resistance in Novel Models of Invasive Lobular Breast Cancer 2008 ·Cancer Research ·Rebecca B. Riggins, (unknown), (unknown), Alan Zwart, Luciane R. Cavalli, Bassem R. Haddad, Li Chen, Ting Gong, Jianhua Xuan, Stephen P. Ethier, Robert Clarke	91
18	The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines 2007 ·Cancer Genetics and Cytogenetics ·Kerrie B. Bouker, Todd C. Skaar, David S. Harburger, Rebecca B. Riggins, David Fernández, Alan Zwart, Robert Clarke	12
19	Mechanisms Mediating the Effects of Prepubertal (n-3) Polyunsaturated Fatty Acid Diet on Breast Cancer Risk in Rats 2005 ·Journal of Nutrition ·Leena Hilakivi‐Clarke, (unknown), Ayesha N. Shajahan‐Haq, Galam Khan, Yuelin J. Zhu, Alan Zwart, Elizabeth Cho, Robert Clarke	37
20	Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis 2005 ·Carcinogenesis ·Kerrie B. Bouker, Todd C. Skaar, Rebecca B. Riggins, David S. Harburger, David Fernández, Alan Zwart, Antai Wang, Robert Clarke	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact